Karlsen, W.;                     Akily, L.;                     Mierzejewska, M.;                     Teodorczyk, J.;                     Bandura, A.;                     Zaucha, R.;                     Cytawa, W.    
        Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons. Cancers 2024, 16, 1990.
    https://doi.org/10.3390/cancers16111990
    AMA Style
    
                                Karlsen W,                                 Akily L,                                 Mierzejewska M,                                 Teodorczyk J,                                 Bandura A,                                 Zaucha R,                                 Cytawa W.        
                Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons. Cancers. 2024; 16(11):1990.
        https://doi.org/10.3390/cancers16111990
    
    Chicago/Turabian Style
    
                                Karlsen, William,                                 Lin Akily,                                 Monika Mierzejewska,                                 Jacek Teodorczyk,                                 Artur Bandura,                                 Renata Zaucha,                                 and Wojciech Cytawa.        
                2024. "Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons" Cancers 16, no. 11: 1990.
        https://doi.org/10.3390/cancers16111990
    
    APA Style
    
                                Karlsen, W.,                                 Akily, L.,                                 Mierzejewska, M.,                                 Teodorczyk, J.,                                 Bandura, A.,                                 Zaucha, R.,                                 & Cytawa, W.        
        
        (2024). Is 18F-FDG-PET/CT an Optimal Imaging Modality for Detecting Immune-Related Adverse Events after Immune-Checkpoint Inhibitor Therapy? Pros and Cons. Cancers, 16(11), 1990.
        https://doi.org/10.3390/cancers16111990